Short-term safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema in children

Archives of Ophthalmology

Volumn 126, Issue 2, 2008, Pages 200-205

  Sallam, Ahmed ^a   Comer, Richard M ^a   Chang, John H ^b   Grigg, John R ^c   Andrews, Richard ^a   McCluskey, Peter J ^b   Lightman, Susan ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b LIVERPOOL HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; SALAZOSULFAPYRIDINE; STEROID; TRIAMCINOLONE ACETONIDE;

ADOLESCENT; CATARACT; CHILD; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; EYE DISEASE; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; MEDICAL RECORD; PHTHISIS BULBI; PRIORITY JOURNAL; RELAPSE; RETINA MACULA CYSTOID EDEMA; REVIEW; UVEA DISEASE; UVEA MACULAR EDEMA; UVEITIS; VISUAL ACUITY;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; GLUCOCORTICOIDS; HUMANS; INJECTIONS; INTRAOCULAR PRESSURE; MACULAR EDEMA; MALE; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; UVEITIS; VISUAL ACUITY; VITREOUS BODY;

EID: 39049169155     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archophthalmol.2007.59     Document Type: Review

References (24)

1. Perkins ES. Patterns of uveitis in children. Br J Ophthalmol. 1966;50(4):169-185.
2. Jain R, Ferrante P, Reddy GT, Lightman S. Clinical features and visual outcome of intermediate uveitis in children. Clin Experiment Ophthalmol. 2005;33(1):22-25.
3. Lustig MJ, Cunningham ET Jr. Use of immunosuppressive agents in uveitis. Curr Opin Ophthalmol. 2003;14(6):399-412.
4. Doycheva D, Deuter C, Stuebiger N, Biester S, Zierhut M. Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol. 2007;91(2):180-184.
5. Kok H, Lau C, Maycock N, McCluskey P, Lightman S. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology. 2005;112(11):1916.e1-1916.e7.
6. Young S, Larkin G, Branley M, Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Experiment Ophthalmol. 2001;29(1):2-6.
7. Androudi S, Letko E, Meniconi M, et al. Safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema. Ocul Immunol Inflamm. 2005;13(2-3):205-212.
8. Angunawela RI, Heatley CJ, Williamson TH, et al. Intravitreal triamcinalone acetonide for refractory uveitic cystoid macular oedema: long term management and outcome. Acta Ophthalmol Scand. 2005;83(5):595-599.
9. Sørensen TL, Haamann P, Villumsen J, Larsen M. Intravitreal triamcinolone for macular oedema: efficacy in relation to aetiology. Acta Ophthalmol Scand. 2005;83(1):67-70.
10. Antcliff RJ, Spalton DJ, Stanford MR. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology. 2001;108(4):765-772.
11. Jonas JB, Kreissig I, Soefker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic maculae edema. Arch Ophthalmol. 2003;121(1):57-61.
12. Karacorlu M, Mudun B, Ozdemir H, Karacorlu SA, Burumcek E. Intravitreal triamcinolone acetonide for the treatment of cystoid macular edema secondary to Behçet disease. Am J Ophthalmol. 2004;138(2):289-291.
13. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina. 2000;20(3):244-250.
14. Inoue M, Takeda K, Morita K, et al. Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection. Am J Ophthalmol. 2004;138(6):1046-1048.
15. Gass JDM, Norton EWD. Cystoid macular edema and papilledema following cataract extraction: a fluorescein fundoscopic and angiographic study. Arch Ophthalmol. 1966;76(5):646-661.
16. Beer PM, Bakri SJ, Singh RJ, Liu W, Peters GB III, Miller M. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003;110(4):681-686.
17. Chin HS, Park TS, Moon YS, Oh JH. Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina. 2005;25(5):556-560.
18. Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol. 2003;87(1):24-27.
19. Wingate RJ, Beaumont PE. Intravitreal triamcinolone and elevated intraocular pressure. Aust N Z J Ophthalmol. 1999;27(6):431-432.
20. Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology. 2005;112(4):593-598.
21. Lam DSC, Fan DSP, Ng JSK, et al. Ocular-hypertensive and anti-inflammatory responses to different dosages of topical dexamethasone in children: a randomized trial. Clin Experiment Ophthalmol. 2005;33(3):252-258.
22. Gillies MC, Simpson JM, Billson FA, et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol. 2004;122(3):336-340.
23. Pallikaris IG, Kymionis GD, Ginis HS, Kounis GA, Tsilimbaris MK. Ocular rigidity in living human eyes. Invest Ophthalmol Vis Sci. 2005;46(2):409-414.
24. Jonas JB, Akkoyun I, Budde WM, Kreissig I, Degenring RF. Intravitreal reinjections of triamcinolone for exudative age-related macular degeneration. Arch Ophthalmol. 2004;122(2):218-222.